⚡ GnRH Agonist

Gonadorelin / GnRH (2 mg Vial) Dosage Protocol

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH) — the decapeptide produced by hypothalamic neurons that stimulates pulsatile LH and FSH release from the pituitary. Used in clinical diagnostics and increasingly in TRT-adjacent protocols to maintain HPG axis function.

⚡ Quickstart Highlights

Reconstitution

2.0 mL BAC water → 1.0 mg/mL

Per-Dose Range

100–250 mcg per injection

1 U-100 Unit =

10 mcg

Half-life

~2–10 minutes

Dosing & Reconstitution Guide

Route: Subcutaneous | Frequency: 2–3× per week (pulsatile protocols)

Application	Dose	Frequency	U-100 Units	Notes
HPG axis maintenance	100 mcg	3× per week	10 units (0.10 mL)	Conservative
Standard research	200–250 mcg	2–3× per week	20–25 units	Common range
Diagnostic stimulation	100 mcg (single)	Once (test dose)	10 units	GnRH stimulation test

Gonadorelin has an extremely short half-life of 2–10 minutes — it is designed for pulsatile secretion. Continuous or very frequent dosing can paradoxically SUPPRESS LH/FSH through receptor desensitization (the same mechanism used by GnRH agonist drugs like leuprolide for prostate cancer). Pulsatile 2–3× per week dosing avoids this.

Reconstitution Steps

Draw 2.0 mL bacteriostatic water into a sterile syringe.
Inject slowly down the inside glass wall of the vial; avoid foaming.
Gently swirl until dissolved. Do not shake.
Label with reconstitution date. Refrigerate at 2–8°C; use within 28 days.

Supplies Planning

Item	8 Weeks (200 mcg 3×/wk)	12 Weeks
Gonadorelin vials (2 mg)	3 vials	4–5 vials
Insulin syringes (30–50 unit)	24	36
Bacteriostatic water (10 mL)	1 × 10 mL	2 × 10 mL
Alcohol swabs	1 × 100-pack	1 × 100-pack

Mechanism of Action

Gonadorelin is the synthetic version of endogenous GnRH (gonadotropin-releasing hormone), a 10-amino acid decapeptide (Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) produced by GnRH neurons in the hypothalamic preoptic area. It binds to GnRH receptors on anterior pituitary gonadotroph cells, stimulating synthesis and pulsatile secretion of LH and FSH.

A critical pharmacological nuance: pulsatile GnRH stimulation (as occurs physiologically every 60–90 minutes) maintains LH and FSH secretion. Continuous GnRH stimulation causes receptor downregulation and desensitization, paradoxically suppressing LH/FSH — this is the mechanism exploited by GnRH agonist drugs (leuprolide, buserelin) for prostate cancer and endometriosis treatment. Research protocols must therefore use intermittent, pulsatile administration rather than continuous infusion.

Research Findings & Safety Profile

Stimulates pulsatile LH and FSH release — maintains HPG axis function during TRT or other hormonal protocols.
Used diagnostically in the GnRH stimulation test to differentiate hypothalamic from pituitary causes of hypogonadism.
Continuous/frequent dosing causes receptor desensitization and LH/FSH suppression — the opposite of the desired effect.
Short half-life (2–10 min) means plasma levels drop rapidly; twice or thrice weekly pulsatile dosing preserves receptor sensitivity.
Increasingly used in research protocols to maintain testicular function and volume alongside TRT.
Possible effects: local injection-site reactions; rare headache or flushing; nausea (uncommon).

Storage

State	Temperature	Duration	Notes
Lyophilized	−20°C (−4°F)	Up to 24 months	Dry, dark conditions
Reconstituted	2–8°C (35–46°F)	Up to 28 days	Avoid freeze-thaw; protect from light

⚠ Research Use Only: Gonadorelin has a critically short half-life — continuous or overly frequent dosing suppresses rather than stimulates LH/FSH. Use pulsatile 2–3× per week protocols. Not FDA approved for the applications described here.

References

Knobil E. 'The Neuroendocrine Control of the Menstrual Cycle' — Recent Prog Horm Res, 1980 View source ↗

Spratt DI et al. 'Pulsatile gonadotropin secretion during fasting in postmenopausal women' — J Clin Endocrinol Metab, 1984